RENOIR phase 3 rituximab-lenalidomide vs rituximab as maintenance treatment in relapsed/refractory follicular lymphoma.

In 30 seconds

The RENOIR phase 3 trial evaluated rituximab plus lenalidomide (R2) versus rituximab alone (R) as maintenance therapy in older patients with relapsed/refractory follicular lymphoma. Among 152 patients, the 2-year progression-free survival (PFS) was 73% for R2 and 64% for R, indicating a numerical benefit for R2, particularly in patients under 70 years of age.

Key findings

• 2-year PFS was 73% in the R2 arm compared to 64% in the R arm.
• In patients aged <70 years, 2-year PFS was 96% for R2 versus 69% for R.
• Two-year overall survival rates were similar: 80% for R2 and 89% for R.
• Grade 3/4 adverse events were more frequent in the R2 group, primarily neutropenia.

Why it matters

This study highlights the ongoing challenges in optimizing maintenance therapy for older patients with relapsed/refractory follicular lymphoma, emphasizing the need for careful assessment of treatment benefits versus risks.